Suppr超能文献

ACEA-1416的药理学:一种强效的全身活性N-甲基-D-天冬氨酸受体甘氨酸位点拮抗剂。

Pharmacology of ACEA-1416: a potent systemically active NMDA receptor glycine site antagonist.

作者信息

Ilyin V I, Whittemore E R, Tran M, Shen K Z, Cai S X, Kher S M, Keana J F, Weber E, Woodward R M

机构信息

Acea Pharmaceuticals Inc., Irvine, CA 92718, USA.

出版信息

Eur J Pharmacol. 1996 Aug 29;310(2-3):107-14. doi: 10.1016/0014-2999(96)00370-6.

Abstract

Excitatory amino acid receptor antagonists show potential for the treatment of ischemic stroke and head trauma. In search of novel antagonists, a series of alkyl- and alkoxyl-substituted 1, 4-dihydro-2,3-quinoxalinediones were synthesized and assayed for inhibition of glutamate receptors. We report on the pharmacological characterization of one such compound, 7-chloro-6-methyl-5-nitro-1,4-dihydro-2, 3-quinoxalinedione (ACEA-1416). Electrophysiological assays showed that ACEA-1416 is a potent antagonist of rat brain NMDA receptors expressed in Xenopus oocytes, and NMDA receptors expressed by cultured rat cortical neurons. Antagonism is via competitive inhibition at glycine co-agonist sites (Kb = 7.9 nM in oocytes, Kb = 11 nM in neurons). ACEA-1416 also antagonizes AMPA receptors, though potency is considerably lower (Kb = 3.5 microM in oocytes, Kb = 1.6 microM in neurons). Oocyte assays indicated that ACEA-1416 is weak or inactive as an antagonist at NMDA receptor glutamate binding sites (Kb > 5.9 microM) and metabotropic glutamate receptors (Kb > 57 microM). Many NMDA receptor glycine site antagonists show poor penetration of the blood-brain barrier. Systemic bioavailability of ACEA-1416 was assessed by measuring the ability of the compound to protect against electroshock-induced seizures in mice. Protective effects of ACEA-1416 had rapid onset following i.v. administration. Peak efficacy was at approximately 2 min and the biological half-time of protection was approximately 60 min. The ED50 measured at peak efficacy was approximately 1.5 mg/kg. Our results show that ACEA-1416 is a high potency systemically active NMDA receptor glycine site antagonist and a moderate potency AMPA receptor antagonist. Separate studies indicate that ACEA-1416 is efficacious as a neuroprotectant in a rat model of focal cerebral ischemia. Taken together, our results suggest that ACEA-1416 has potential for clinical development as a neuroprotectant.

摘要

兴奋性氨基酸受体拮抗剂在缺血性中风和头部创伤的治疗中显示出潜力。为了寻找新型拮抗剂,合成了一系列烷基和烷氧基取代的1,4 - 二氢 - 2,3 - 喹喔啉二酮,并检测它们对谷氨酸受体的抑制作用。我们报告了一种此类化合物7 - 氯 - 6 - 甲基 - 5 - 硝基 - 1,4 - 二氢 - 2,3 - 喹喔啉二酮(ACEA - 1416)的药理学特性。电生理实验表明,ACEA - 1416是非洲爪蟾卵母细胞中表达的大鼠脑NMDA受体以及培养的大鼠皮层神经元表达的NMDA受体的强效拮抗剂。其拮抗作用是通过对甘氨酸共激动剂位点的竞争性抑制实现的(在卵母细胞中Kb = 7.9 nM,在神经元中Kb = 11 nM)。ACEA - 1416也能拮抗AMPA受体,不过效力要低得多(在卵母细胞中Kb = 3.5 μM,在神经元中Kb = 1.6 μM)。卵母细胞实验表明,ACEA - 1416作为NMDA受体谷氨酸结合位点的拮抗剂作用较弱或无活性(Kb > 5.9 μM),对代谢型谷氨酸受体也是如此(Kb > 57 μM)。许多NMDA受体甘氨酸位点拮抗剂的血脑屏障穿透性较差。通过测量该化合物预防小鼠电休克诱导癫痫发作的能力来评估ACEA - 1416的全身生物利用度。静脉注射后,ACEA - 1416的保护作用起效迅速。峰值疗效出现在约2分钟时,保护作用的生物半衰期约为60分钟。峰值疗效时测得的ED50约为1.5 mg/kg。我们的结果表明,ACEA - 1416是一种高效的全身活性NMDA受体甘氨酸位点拮抗剂和中等效力的AMPA受体拮抗剂。单独的研究表明,ACEA - 1416在局灶性脑缺血大鼠模型中作为神经保护剂是有效的。综上所述。综上所述,我们的结果表明ACEA - 1416有作为神经保护剂进行临床开发的潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验